Effect of beta-pyridyl-carbinol on platelet aggregation.
We studied the anti-platelet aggregation activity of beta-pyridyl-carbinol (b-PC) (Ronicol, Roche). This compound has a chemical structure similar to nicotinic acid and is therapeutically indicated in functional and organic circulatory processes. We determined the in vitro antiaggregation activity induced by ADP (4 microM) and collagen (20 micrograms/ml) using Cardinal and Flower's technique. Antithrombotic activity was assessed in rats by measuring the duration of ADP-induced (12.40 micrograms/kg i.v.) respiratory dysfunction in 2 groups: one given 17.14 mg/kg beta-pyridyl-carbinol for 8 consecutive days before testing and controls. In vitro and in vivo results were highly significant. Circulating platelet count increased in b-PC treated animals. Systolic and diastolic pressures remained unmodified during administration of b-PC.
Manzanares
J
J
Departamento de Farmacología, Facultad de Farmacia, Universidad Complutense, Madrid, Spain.
Cantón
R
R
Zaragoza
F
F
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D009540:Nicotinyl Alcohol / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010976:Platelet Count; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; D009540:Nicotinyl Alcohol